MIRA
INFORM REPORT
|
Report Date : |
12.10.2013 |
IDENTIFICATION DETAILS
|
Name : |
CADILA PHARMACEUTICALS LIMITED |
|
|
|
|
Registered
Office : |
Cadila Corporate Campus, Sarkhej Dhokla Road, Ahmedabad – 380008,
Gujarat |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2012 |
|
|
|
|
Date of
Incorporation : |
28.02.1991 |
|
|
|
|
Com. Reg. No.: |
04-015132 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.800.000 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24231GJ1991PLC015132 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
AHMC0038ID |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACC6251E |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of Pharmaceutical
Products. |
|
|
|
|
No. of Employees
: |
5000 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (55) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 9270000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Exist |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having fine track
record. Financial position of the company appears to be sound. Trade
relations are reported as trustworthy. Business is active. Payments are
reported to be regular and as per commitments. The company can be considered good for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EXTERNAL AGENCY RATING
|
Rating Agency Name |
CARE |
|
Rating |
BBB+ (Long Term Bank Facilities) |
|
Rating Explanation |
Moderate degree of safety and moderate
credit risk. |
|
Date |
April 2013 |
|
Rating Agency Name |
CARE |
|
Rating |
A2 (Short Term Bank Facilities) |
|
Rating Explanation |
Strong degree of safety and low credit risk.
|
|
Date |
April 2013 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION DENIED
Management Non-Cooperative (91-2718-225001)
LOCATIONS
|
Registered/ Corporate Office
: |
Cadila Corporate Campus, Sarkhej
- |
|
Tel. No.: |
91-2718-225001 (15 Lines) |
|
Fax No.: |
91-2718-225039 |
|
E-Mail : |
secretarial@cadilapharma.co.in purchase@cadilapharma.com |
|
Website: |
|
|
Area : |
44 Acres |
|
Location : |
Owned |
|
|
|
|
Factory 1: |
Dholka – Manufacturing Plant Survey No. 1389, Trasad Road,
Dholka, Ahmedabad – 387810, Gujarat, India |
|
Tel. No: |
91-79-23421841/83/ 84/ 3422006/
7/ 8/ 9/ 10 |
|
Fax No: |
91-79-23420315s/ 3421220 |
|
Area: |
50000 sq. ft. |
|
Location : |
Owned |
|
|
|
|
Factory 2: |
Chemical SBU 294, GIDC Estate, Ankleshwar, Gujarat, India |
|
Tel. No: |
91-2646-223846 / 252626 / 251519 |
|
Fax No: |
91-2646-250051 |
|
|
|
|
Factory 3: |
CHPL – Factory / Karnavati
Engineering Limited Survey No. 342, Nani Kadi,
Taluka Kadi, District Mehsana, North
Gujarat, |
|
Tel. No: |
91-2764-262463 / 242037 / 242194
/ 241464-65 |
|
Fax No: |
91-2764-242223 / 242608 |
|
Location : |
Owned |
|
|
|
|
Factory 4: |
Chemicals SBU Factory Plot No. 274, GIDC Industrial Estate, Ankleshwar, |
|
Tel. No: |
91-2646-223846 / 252626 / 251519 |
|
Fax No: |
91-2646-250051 |
|
Area: |
174557 sq. ft. |
|
Location : |
Owned |
|
|
|
|
Factory 5: |
Tissu Culture Lab 756, Prakruti Farm, Hirapur
Chowkdi, Hirapur, Ahmedabad, Gujarat, India |
|
Tel. No: |
91-79-3855260/3855495/496 |
|
Location : |
Owned |
|
|
|
|
Factory 6: |
Cadila Pharmaceuticals Limited, Jammu Industrial Growth Centre, Samba – 184121, District Jammu,
Jammu and Kashmir, India |
|
Tel. No: |
91-1923-241113 / 241114 / 241115 |
|
Fax No: |
91-1923-246744 |
DIRECTORS
AS ON 28.09.2012
|
Name : |
Dr. Rajiv Indravadan Modi |
|
Designation : |
Managing Director |
|
Address : |
13, Sanjiv Building, New Sharda
Mandir Road, Paldi, Ahmedabad –
380007, Gujarat, India |
|
Date of Birth/Age : |
09.05.1960 |
|
Qualification : |
Ph. D (Biological Science), M. Sc (Biochemical Engineering), B. Tech(Chemical Engineering) |
|
Date of Appointment : |
01.07.2010 |
|
PAN No.: |
AAPPM9265J |
|
Din No.: |
01394558 |
|
|
|
|
Name : |
Prof. Atul Bipinbhai Tandon |
|
Designation : |
Director |
|
Address : |
A/43, Royal Orchid, Corporate
Road, Opposite Prahlad Nagar Gardens, Prahlad Nagar, Ahmedabad – 380015,
Gujarat, India |
|
Date of Birth/Age : |
03.01.1948 |
|
Qualification : |
B. Tech from I.I.T, Bombay and PGDBA from IIM, Ahmedabad |
|
Date of Appointment : |
04.07.2003 |
|
Din No.: |
00165667 |
|
|
|
|
Name : |
Mrs. Monika Garware Modi |
|
Designation : |
Director |
|
Address : |
13, Sanjiv Building, New Sharda
Mandir Road, Paldi, Ahmedabad – 380
007, Gujarat, India |
|
Date of Birth/Age : |
04.06.1963 |
|
Qualification : |
M.B.A. from Pace University, New York, USA |
|
Date of Appointment : |
15.12.1995 |
|
PAN No.: |
AEQPG3834C |
|
Din No.: |
00143400 |
|
|
|
|
Name : |
Mr. Chinubhai Ramanlal Shah |
|
Designation : |
Director |
|
Address : |
402, Heritage Cresent, |
|
Date of Birth/Age : |
04.06.1937 |
|
Qualification : |
M.A., L.L.M. (Gold Medalist), DLP, DTP, FCS, Life Fellow AIMA |
|
Date of Appointment : |
31.03.2001 |
|
Din No.: |
00558310 |
|
|
|
|
Name : |
Prof. Pradip Navin Khandwalla |
|
Designation : |
Director |
|
Address : |
B/101, |
|
Date of Birth/Age : |
18.02.1940 |
|
Qualification : |
B. Com. (Bom), MBA (Wharton, Penn.), Ph.D. (Carnegie-Mellon), ACA |
|
Date of Appointment : |
14.09.2007 |
|
Din No.: |
00064643 |
|
|
|
|
Name : |
Mrs. Shilaben Indravadan Modi |
|
Designation : |
Director |
|
Address : |
13, Sanjiv Baug, New |
|
Date of Birth/Age : |
09.12.1931 |
|
Qualification : |
Matriculate |
|
Date of Appointment : |
16.12.1995 |
|
PAN No.: |
AEYPM8647R |
|
Din No.: |
01976356 |
|
|
|
|
Name : |
Mr. Sanjay Sinha |
|
Designation : |
Director |
|
Address : |
A/ 31, Orchid Woods, Opposite
Vodafone House, Prahlad Nagar, Corporate Road, Ahmedabad – 380015, Gujarat,
India |
|
Date of Birth/Age : |
01.11.1958 |
|
Date of Appointment : |
29.09.2012 |
|
Din No.: |
03627342 |
|
|
|
|
Name : |
Mr. Daya Nand Khurana |
|
Designation : |
Director |
|
Address : |
288, Vasant Enclave, Vasant Vihar, New Delhi-110057, India |
|
Date of Birth/Age : |
15.05.1935 |
|
Qualification : |
B.E.(EC) |
|
Date of Appointment : |
04.07.2003 |
|
Din No.: |
00020601 |
KEY EXECUTIVES
|
Name : |
Mr. Shreyas Kunjvuhari Parikh |
|
Designation : |
Company Secretary |
|
Address : |
B 001, Aakasheep Anne, Near
Shreyas Railway Crossing, Amba Wadi, Ahmedabad – 380 006, |
|
Date of Birth/Age : |
12.08.1957 |
|
Date of Appointment : |
22.02.2008 |
|
Pan No.: |
AEIPP6513R |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 28.09.2012
|
Names of Shareholders |
|
No. of Shares |
|
Indravadan A Modi |
|
7999990 |
|
Shilaben I Modi |
|
7999990 |
|
I. A. Modi |
|
59460955 |
|
I. A. Modi (HUF) |
|
10 |
|
Shilaben I Modi |
|
13333 |
|
R. I. Modi |
|
4525712 |
|
I. A. Modi |
|
10 |
|
|
|
|
|
TOTAL
|
|
80000000 |
AS ON 28.09.2012
|
Equity Share Breakup |
|
Percentage of Holding |
|
Category |
|
|
|
Bodies
corporate |
|
80.00 |
|
Directors
or relatives of directors |
|
20.00 |
|
TOTAL |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical
Products. |
||||||||
|
|
|
||||||||
|
Products : |
|
PRODUCTION STATUS (AS ON 31.03.2011)
|
Particulars |
Unit |
Installed
Capacity |
Actual
Production |
|
Tablets |
Nos in million |
14913 |
6116 |
|
Capsules |
Nos in million |
1124 |
300 |
|
Injections |
Kilo Litres |
298 |
216 |
|
Liquids |
Kilo Litres |
10376 |
2071 |
|
Ophthalmic |
Kilo Litres |
0 |
24 |
|
Ointment |
M.T |
0 |
6 |
|
Dry powder injections |
M.T |
10 |
5 |
|
Granules and dry syrups |
M.T |
220 |
1 |
|
Bulk drugs |
M.T |
979 |
1069 |
|
Tissue cultures |
Nos in million |
10 |
10 |
NOTES:
1. As the Industrial
licensing in respect of Drugs and Pharmaceuticals produced by the Company has
been waived, the particulars of licensed capacity are not stated.
2. The installed capacity
is taken on 2 shift working, as Certified by Management.
3. Production
includes production under Loan License arrangement.
GENERAL INFORMATION
|
No. of Employees : |
5000 (Approximately) |
|||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
Bankers : |
·
Central Bank of India,
Central Bank Building, Lal Darwaja, Ahmedabad – 380 001, Gujarat, India ·
Bank of Baroda ,
Corporate Financial Services Branch, 1st Floor, BOB Towers,
Opposite Law Garden, Ellis Bridge, Ahmedabad-380009, Gujarat, India ·
Corporation Bank,
Avrangpura Branch, Ahmedabad, Gujarat, India ·
Oriental Bank of
Commerce, Ashram Road, Ahmedabad, Gujarat, India ·
Punjab National
Bank, Ashram Road Branch, Satellite, Ahmedabad – 380 009, Gujarat, India ·
Union Bank of India,
Industrial Finance Branch, Ashram Road, Ahmedabad, Gujarat, India ·
Syndicate Bank,
Ashram Road Branch, Ahmedabad-380 009, Gujarat, India ·
ICICI Bank, Bandra,
Mumbai, Maharashtra, India ·
Canara Bank, Bhadra
Branch, Ahmedabad - 380001 ·
Export Import Bank
of India, Centre One, World Trade Centre, Cuffe Parade, Mumbai-400005,
Maharashtra, India ·
State Bank of India,
Corporate Account Group, Cuffe Parade, 58, Shrimali Society, Navrangpura,
Ahmedabad, Gujarat, India ·
Allahabad Bank,
Ashram Road Branch, Ahmedabad-380014, Gujarat, India ·
HDFC Bank Limited, HDFC
Bank House Senapati Bapat Marg, Lower Parel West, Mumbai – 400013,
Maharashtra, India ·
The Karnataka Bank
Limited, Shree Gantha Karna Mahavee Complex, Near New Cloth Market,
Sarangpura, Ahmedabad- 380002, Gujarat, India ·
Axis Bank Limited,
Ahmedabad, Gujarat, India ·
Bank of Maharashtra ·
State Bank of Mysore ·
Dena Bank ·
State Bank of
Saurashtra ·
Tamilnadu
Mercantile Co-operative Bank Limited ·
Vijaya Bank |
|||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
Facilities : |
|
|||||||||||||||||||||||||||
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Financial
Institution : |
Department of Biotechnology, Block 2, CGO Complex, Lodhi Road, New
Delhi-110003, India |
|
|
|
|
Auditors : |
|
|
Name : |
Deloitte Haskins and Sells Chartered Accountants |
|
Address : |
‘Heritage’, 3rd Floor,
Near Gujarat Vidhyapith, Off Ashram Road, Ahmedabad – 380 014, Gujarat, India |
|
Tel. No.: |
91-79-27582542/ 27582543/
266073100 |
|
Fax No.: |
91-79-27582551 |
|
E-Mail : |
|
|
PAN No: |
AABFD7919A |
|
|
|
|
Joint Venture : |
·
Apollo Hospitals International Limited
[U85110TN1997PLC039016] ·
Casil Bg Medical Devices Private Limited
[U24230GJ2012PTC069227] |
|
|
|
|
Subsidiaries : |
·
SOHL, UK ·
Cadila Pharmaceuticals (Ethiopia) Plc ·
CPL Biologicals Private Limited
[U01403GJ2009PTC056409] ·
Kadera Yakuhin Limited ·
CPL Holdings Private Limited
[U65993GJ2009PTC056511] ·
CPL Agro Products Private Limited
[U01403GJ2009PTC056669] ·
Cadila East Africa Limited ·
CPL Inc ·
Casil Industries Limited [U24231GJ2000PLC038320] ·
Interpharma Industries Limited ·
Casil Health Products Limited
[U51909GJ1995PLC027839] |
|
|
|
|
Other Related Parties : |
·
CPL Infrastructure Private Limited
[U67120GJ1995PTC025713] ·
IRM Enterprises Private Limited ·
Karnavati Engineering Limited
[U29199GJ1981PLC004488] |
CAPITAL STRUCTURE
AS ON 31.03.2012
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
80000000 |
Equity Shares |
Rs.10/- each |
Rs.800.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
80000000 |
Equity Shares |
Rs.10/- each |
Rs.800.000 Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
|
31.03.2012 |
31.03.2011 |
|
EQUITY AND
LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
|
800.000 |
800.000 |
|
(b) Reserves & Surplus |
|
1519.643 |
1427.297 |
|
(c) Money received against share warrants |
|
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money pending allotment |
|
0.000 |
0.000 |
|
Total Shareholders’
Funds (1) + (2) |
|
2319.643 |
2227.297 |
|
|
|
|
|
|
(3) Non-current
liabilities |
|
|
|
|
(a) long-term borrowings |
|
3562.681 |
3114.053 |
|
(b) Deferred tax liabilities (Net) |
|
506.056 |
490.447 |
|
(c) Other long term liabilities |
|
216.066 |
225.954 |
|
(d) long-term provisions |
|
22.199 |
20.447 |
|
Total Non-current
Liabilities (3) |
|
4307.002 |
3850.901 |
|
|
|
|
|
|
|
|
|
|
|
(4) Current
liabilities |
|
|
|
|
(a) Short term borrowings |
|
1454.878 |
1379.937 |
|
(b) Trade payables |
|
1407.434 |
1022.431 |
|
(c) Other current liabilities |
|
1386.490 |
1238.844 |
|
(d) Short-term provisions |
|
82.385 |
34.384 |
|
Total Current
Liabilities (4) |
|
4331.187 |
3675.596 |
|
|
|
|
|
|
TOTAL |
|
10957.832 |
9753.794 |
|
|
|
|
|
|
I. ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i) Tangible assets |
|
3452.190 |
3399.715 |
|
(ii) Intangible Assets |
|
20.862 |
16.004 |
|
(iii) Capital work-in-progress |
|
467.041 |
444.523 |
|
(iv) Intangible assets under development |
|
50.104 |
0.000 |
|
(b) Non-current Investments |
|
1308.584 |
1197.025 |
|
(c) Deferred tax assets (net) |
|
0.000 |
0.000 |
|
(d) Long-term Loan and Advances |
|
995.731 |
740.789 |
|
(e) Other Non-current assets |
|
0.000 |
0.000 |
|
Total Non-Current
Assets |
|
6294.512 |
5798.056 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a) Current investments |
|
0.000 |
0.000 |
|
(b) Inventories |
|
1535.482 |
1506.732 |
|
(c) Trade receivables |
|
2299.033 |
1781.776 |
|
(d) Cash and cash equivalents |
|
168.657 |
201.900 |
|
(e) Short-term loans and advances |
|
543.030 |
348.512 |
|
(f) Other current assets |
|
117.118 |
116.818 |
|
Total Current
Assets |
|
4663.320 |
3955.738 |
|
|
|
|
|
|
TOTAL |
|
10957.832 |
9753.794 |
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
|
|
31.03.2010 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
|
|
800.000 |
|
|
2] Share Application Money |
|
|
0.000 |
|
|
3] Reserves & Surplus |
|
|
1332.124 |
|
|
4] (Accumulated Losses) |
|
|
0.000 |
|
|
NETWORTH |
|
|
2132.124 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
|
|
3754.357 |
|
|
2] Unsecured Loans |
|
|
697.619 |
|
|
TOTAL BORROWING |
|
|
4451.976 |
|
|
DEFERRED TAX LIABILITIES |
|
|
462.131 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
7046.231 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
|
3382.072 |
|
|
Capital work-in-progress |
|
|
102.845 |
|
|
|
|
|
|
|
|
INVESTMENT |
|
|
1138.500 |
|
|
DEFERREX TAX ASSETS |
|
|
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
|
|
1148.883
|
|
|
Sundry Debtors |
|
|
1601.648
|
|
|
Cash & Bank Balances |
|
|
274.876
|
|
|
Other Current Assets |
|
|
0.000
|
|
|
Loans & Advances |
|
|
992.624
|
|
Total
Current Assets |
|
|
4018.031 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
|
|
1050.234
|
|
|
Other Current Liabilities |
|
|
493.928
|
|
|
Provisions |
|
|
51.055
|
|
Total
Current Liabilities |
|
|
1595.217
|
|
|
Net Current Assets |
|
|
2422.814
|
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
|
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
7046.231 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
9180.544 |
7816.194 |
6478.223 |
|
|
|
Other Income |
115.540 |
84.339 |
250.545 |
|
|
|
TOTAL (A) |
9296.084 |
7900.533 |
6728.768 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of materials consumed |
3127.037 |
2935.607 |
|
|
|
|
Purchases of stock-in-trade |
650.190 |
530.257 |
|
|
|
|
Employee benefit expense |
1485.235 |
1199.865 |
|
|
|
|
Other expenses |
2580.769 |
2415.274 |
6056.171 |
|
|
|
Exceptional items |
404.260 |
253.960 |
|
|
|
|
Changes in
inventories of finished goods, work-in-progress and stock-in-trade |
(14.338) |
(278.820) |
|
|
|
|
TOTAL (B) |
8233.153 |
7056.143 |
6056.171 |
|
|
|
|
|
|
|
|
Less |
PROFIT
/ (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
1062.931 |
844.390 |
672.597 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
609.876 |
444.627 |
424.465 |
|
|
|
|
|
|
|
|
|
|
PROFIT
/ (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
453.055 |
399.763 |
248.132 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
255.268 |
242.856 |
221.698 |
|
|
|
|
|
|
|
|
|
|
PROFIT / (LOSS)
BEFORE TAX (E-F) (G) |
197.787 |
156.907 |
26.434 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
55.932 |
61.734 |
8.705 |
|
|
|
|
|
|
|
|
|
|
PROFIT / (LOSS)
AFTER TAX (G-H) (I) |
141.855 |
95.173 |
17.729 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
1272.946 |
1177.773 |
1160.044 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
1414.801 |
1272.946 |
1177.773 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN FOREIGN
CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
2927.473 |
NA |
NA |
|
|
|
Royal Income |
12.042 |
NA |
NA |
|
|
TOTAL EARNINGS |
2939.515 |
NA |
NA |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
|
237.146 |
149.845 |
|
|
|
Research material |
|
4.674 |
3.306 |
|
|
|
Stores and spares |
|
16.410 |
4.335 |
|
|
|
Capital goods |
|
140.428 |
116.428 |
|
|
|
Packing material |
|
4.212 |
1.173 |
|
|
TOTAL IMPORTS |
336.261 |
402.870 |
275.087 |
|
|
|
|
|
|
|
|
|
|
Earnings /
(Loss) Per Share (Rs.) |
1.77 |
1.19 |
0.22 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
PAT / Total Income |
(%) |
1.53
|
1.20 |
0.26
|
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
2.15
|
2.00 |
0.41
|
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
2.17
|
1.93 |
0.35
|
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.09
|
0.07 |
0.01
|
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt/Networth) |
|
2.16
|
2.02 |
2.09
|
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.08
|
1.03 |
2.52
|
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by
Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
Yes |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
Yes |
|
9] |
Name of person contacted |
Yes |
|
10] |
Designation of contact person |
Yes |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
-- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
Yes |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm / promoter involved in |
Yes |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
PAN of Proprietor/Partner/Director, if available |
Yes |
|
32] |
Date
of Birth of Proprietor/Partner/Director, if available |
Yes |
|
33] |
Voter ID No of Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating, if available |
Yes |
LITIGATION DETAILS
|
HIGH COURT OF GUJARAT |
|
SPECIAL CIVIL APPLICATION No. 419 of 2013 |
|
|
|
|
|
Status :PENDING |
( Converted from : ST/17405/2012 ) |
CCIN No : 001021201300419 |
|
|
||||
|
|
|
S.NO. |
Name of the
Petitioner |
Advocate On Record |
|
1 |
RAPTAKOS BRETT AND COMPANY LIMITED |
MR DAKSHESH MEHTA for: Petitioner(s) |
1|
S.NO. |
Name of the
Respondant |
Advocate On Record |
|
1 |
INTELLECTUAL PROPERTY APPELLATE BOARD |
NOTICE UNSERVED for :Respondent(s) |
|
Presented On |
: 29/12/2012 |
Registered On |
: 15/01/2013 |
|
Bench Category |
: SINGLE BENCH |
District |
: AHMEDABAD |
|
Case Originated
From |
: THROUGH ADVOCATE |
Listed |
: 9 times |
|
StageName |
: NOTICE & ADJOURNED MATTERS |
||
|
Office Objection |
|
|
Filing Stage |
WHETHER INDEX-CUM-CHRONOLOGY OF DOCUMNETS AND EVENTS FILED ? WHETHER PROPER & FULL COURT FEE IS PAID ? WHETHER PAGING IS DONE ? WHETHER COPIES ARE LEGIBLE AND WHETHER TYPED COPIES OF HAND WRITTEN ANNEXURES FILED ? WHETHER COPIES ARE TRUE COPIES SO SIGNED BY ADVOCATE ? |
|
Classification |
SJ - NON-SERVICE - TRADE MARKS ACT, 1999 |
|
Act |
TRADE UNIONS ACT, 1926 |
|
Office Details |
|
S. No. |
Filing Date |
Document Name |
Advocate Name |
Court Fee on
Document |
Document Details |
|
1 |
29/12/2012 |
VAKALATNAMA |
MR DAKSHESH MEHTA ADVOCATE |
5 |
MR DAKSHESH MEHTA:1 |
|
2 |
29/12/2012 |
MEMO OF APPEAL/PETITION/SUIT |
MR DAKSHESH MEHTA ADVOCATE |
50 |
MR DAKSHESH MEHTA:1 |
|
3 |
15/01/2013 |
VAKALATNAMA |
MR YJ TRIVEDI ADVOCATE |
4 |
MR YJ TRIVEDI:2 |
|
4 |
15/01/2013 |
VAKALATNAMA |
MR DAKSHESH MEHTA ADVOCATE |
- |
MR DAKSHESH MEHTA:1 |
|
5 |
15/01/2013 |
DOCUMENT |
NOTICE SERVED |
- |
NOTICE SERVED:3 |
|
6 |
15/01/2013 |
DOCUMENT |
NOTICE UNSERVED |
- |
NOTICE UNSERVED:1 |
|
7 |
14/02/2013 |
MEMO OF APPEAL/PETITION/SUIT |
MR DAKSHESH MEHTA ADVOCATE |
50 |
MR DAKSHESH MEHTA:1 |
|
8 |
04/04/2013 |
VAKALATNAMA |
MR YJ TRIVEDI ADVOCATE |
5 |
MR YJ TRIVEDI:2 |
|
9 |
13/06/2013 |
APPEARANCE NOTE |
MR HRIDAY BUCH ADVOCATE |
0 |
MR HRIDAY BUCH(2372), for R:3 |
|
10 |
14/06/2013 |
AFFIDAVIT IN REPLY |
MR YJ TRIVEDI ADVOCATE |
0 |
MR YJ TRIVEDI(948) for R:2 |
|
Court Proceedings |
|||||
|
S. No. |
Notified Date |
CourtCode |
Board Sr. No. |
Stage |
Action |
Coram |
|
1 |
15/01/2013 |
1 |
- |
OFFICE OBJECTION (FILING STAGE) |
NEXT DATE |
ADDITIONAL REGISTRAR ( JUDICIAL) |
|
2 |
17/01/2013 |
1 |
43 |
OFFICE OBJECTION (FILING STAGE) |
NEXT DATE |
HONOURABLE MR.JUSTICE Z.K.SAIYED |
|
3 |
01/03/2013 |
1 |
3 |
OFFICE OBJECTION REMOVED |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
4 |
08/03/2013 |
1 |
6 |
BOARD NO. I (NOTICE & ADJOURNED MATTERS) |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
5 |
22/03/2013 |
1 |
36 |
FOR REGULAR ADMISSION |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
6 |
05/04/2013 |
1 |
21 |
BOARD NO. I (NOTICE & ADJOURNED MATTERS) |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
7 |
26/04/2013 |
1 |
74 |
BOARD NO. I (NOTICE & ADJOURNED MATTERS) |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
8 |
14/06/2013 |
1 |
55 |
NOTICE &ADJOURNED MATTERS |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
9 |
05/07/2013 |
1 |
92 |
NOTICE & ADJOURNED MATTERS |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
10 |
10/07/2013 |
1 |
37 |
NOTICE & ADJOURNED MATTERS |
NEXT DATE |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
11 |
17/07/2013 |
1 |
- |
NOTICE & ADJOURNED MATTERS |
undefined |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
|
Available Orders |
||||||
|
S. No. |
Case Details |
Judge Name |
Order Date |
CAV |
Judgement |
View |
Download |
|
1 |
SPECIAL CIVIL APPLICATION/419/2013 |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
08/03/2013 |
N |
N |
View |
Download |
|
2 |
SPECIAL CIVIL APPLICATION/419/2013 |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
22/03/2013 |
N |
N |
View |
Download |
|
3 |
SPECIAL CIVIL APPLICATION/419/2013 |
HONOURABLE THE CHIEF JUSTICE MR. BHASKAR BHATTACHARYA HONOURABLE MR.JUSTICE J.B.PARDIWALA |
14/06/2013 |
N |
N |
View |
Download |
REVIEW OF
OPERATIONS:
During the year,
the net sales increased to Rs.9180.540 Millions from Rs. 7816.190 Millions of previous
year, registering a growth of about 17%. Profit before tax (PBT) improved to
Rs. 197.790 Millions and Profit after tax (PAT) to Rs. 141.860 Millions in the
current year as against PBT of Rs. 156.910 Millions and PAT of Rs. 95.170
Millions of the previous year.
The Company
decided to expand its geographical reach the world over, both in API and
Formulations. As a result, this year the Company has export sales of
Rs.2927.470 Millions as against Rs.2108.070 Millions in the previous year,
registering a substantial growth of about 39%.
The Company is
committed to introduce new products / molecules with its R and D efforts in the
coming years and achieve substantial growth in sales as well as profitability.
UNSECURED LOAN
|
Particular |
As
on 31.03.2012 [Rs.
in Millions] |
As
on 31.03.2011 [Rs.
in Millions] |
|
LONG TERM
BORROWINGS |
|
|
|
Public Deposits |
7.242 |
3.818 |
|
Loans and Advances From Related Parties |
562.023 |
410.191 |
|
Other Loans and Advances |
319.443 (B) |
347.570 |
|
|
|
|
|
TOTAL
|
888.708 |
761.579 |
|
NOTE: (B) From Others [
Deptt. of Science and Technology]* * Loan under Pharmaceutical Research and Development Programme. |
||
INDEX OF CHARGES
|
S.No. |
Charge ID |
Date of Charge
Creation/Modification |
Charge amount
secured |
Charge Holder |
Address |
Service Request
Number (SRN) |
|
1 |
10384789 |
17/10/2012 |
500,000,000.00 |
BANK OF BARODA |
CORPORATE FINANCIAL SERVICES BRANCH, BANK OF BARODA TOWERS,
ELLISBRIDGE, AHMEDABAD, GUJARAT - 38000 |
B61496022 |
|
2 |
10349308 |
09/04/2012 |
420,000,000.00 |
Export-Import Bank of India |
CENTRE ONE BUILDING, FLOOR 21, WORLD TRADE CENTRE COMPLEX, CUFFE PARADE, MUMBAI, MAHARASHTRA - 400 005, INDIA |
B37458825 |
|
3 |
10329665 |
20/12/2011 |
650,000,000.00 |
BANK OF BARODA |
CORPORATE FINANCIAL SERVICES BRANCH, BANK OF BARODA TOWERS, ELLISBRIDGE, AHMEDABAD, GUJARAT - 38000 6, INDIA |
B29858016 |
|
4 |
10284330 |
18/04/2011 |
650,000,000.00 |
INDIAN OVERSEAS BANK |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT - 380009, |
B11684461 |
|
5 |
10260601 |
21/12/2010 |
480,000,000.00 |
BANK OF BARODA |
CORPORATE FINANCIAL SERVICES BRANCH, BANK OF BARODA TOWERS, ELLISBRIDGE, AHMEDABAD, GUJARAT - 380006, INDIA |
B03237732 |
|
6 |
10223597 |
26/05/2010 |
400,000,000.00 |
CENTRAL BANK OF INDIA |
CENTRAL BANK BUILDING, LAL DARWAJA, AHMEDABAD, GUJARAT - 380001, INDIA |
A87063632 |
|
7 |
10217064 |
06/08/2011 * |
300,000,000.00 |
Export-Import Bank of India |
CENTRE ONE BUILDING, FLOOR 21, WORLD TRADE CENTRE COMPLEX, CUFFEE PARADE, MUMBAI, MAHARASHTRA - 400005, INDIA |
B19610864 |
|
8 |
10197188 |
11/12/2009 |
250,000,000.00 |
CENTRAL BANK OF INDIA |
LAL DARWAJA, AHMEDABAD, GUJARAT - 380001, INDIA |
A77089563 |
|
9 |
10157250 |
08/04/2009 |
2,550,000.00 |
Department of Biotechnology |
BLOCK 2, CGO COMPLEX, LODHI ROAD, NEW DELHI, DELHI - 110003, INDIA |
A61567855 |
|
10 |
10150957 |
27/03/2009 |
1,400,000,000.00 |
DENA BANK |
INDUSTRIAL FINANCE BRANCH, 2ND FLOOR, , DENA LAXMI BUILDING, 188A, ASHRAM ROAD, AHMEDABAD, GUJARAT - 380009, INDIA |
A59825901 |
|
11 |
10090235 |
31/01/2008 |
4,320,000.00 |
HDFC BANK LIMITED |
HDFC BANK HOUSESENAPATI BAPAT MARG, LOWER PAREL W, MUMBAI, MAHARASHTRA - 400013, INDIA |
A33032723 |
|
12 |
10084310 |
15/03/2010 * |
104,000,000.00 |
CANARA BANK |
OPP ADVANCE CINEMA, BHADRA, AHMEDABAD, GUJARAT - 380001, INDIA |
A82495987 |
|
13 |
10019671 |
31/07/2006 |
250,000,000.00 |
Corporation Bank |
NAVRANGPURA BRANCH, NAVRANGPURA,, AHMEDABAD, GUJARAT - 380009, INDIA |
A04779260 |
|
14 |
10014527 |
26/10/2007 * |
150,000,000.00 |
SYNDICATE BANK |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT - 380009, INDIA |
A27956168 |
|
15 |
90103410 |
12/03/2013 * |
2,100,000,000.00 |
BANK OF BARODA |
CORPORATE FINANCIAL SERVICES BRANCH, 1ST FLOOR, BOB TOWERS, OPP. LAW GARDEN, ELLISBRIDGE, AHMEDABAD, GUJARAT - 380009, INDIA |
B72156987 |
|
16 |
90103321 |
06/10/2003 |
40,000,000.00 |
CANARA BANK |
BHADRA BRANCH, AHMEDABAD, GUJARAT - 380001, INDIA |
- |
|
17 |
90103308 |
18/04/2003 |
30,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT - 380009, INDIA |
- |
|
18 |
90103304 |
28/03/2003 |
225,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT, INDIA |
- |
|
19 |
90103292 |
23/10/2002 |
50,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT - 380009, INDIA |
- |
|
20 |
90103281 |
12/03/2013 * |
2,100,000,000.00 |
BANK OF BARODA |
CORPORATE FINANCIAL SERVICES BRANCH, BOB TOWERS, OPP. LAWGARDEN, ELLISBRIDGE, AHMEDABAD, GUJARAT - 380009, INDIA |
B72159221 |
|
21 |
90103277 |
12/04/2002 |
20,000,000.00 |
CANARA BANK |
BHADRA BRANCH, AHMEDABAD, GUJARAT - 380001, INDIA |
|
|
22 |
90103273 |
22/03/2002 |
15,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT, INDIA |
|
|
23 |
90103269 |
21/01/2002 |
3,100,000.00 |
UNION BANK OF INDIA |
INDUSTRIAL FINANCE BRANCH, ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT - 380014, INDIA |
|
|
24 |
90103245 |
28/05/2001 |
5,000,000.00 |
CORPORATION BANK |
NAVRANGPURA BRANCH, AHMEDABAD, GUJARAT, INDIA |
|
|
25 |
90103234 |
27/03/2002 * |
100,000,000.00 |
EXPROT- IMPORT BANK OF INDIA |
CENTRE 1; FLOOR21, WORLD TRADE CENTRE; CUFFE PARADE, MUMBAI, MAHARASHTRA - 400005, INDIA |
|
|
26 |
90103226 |
08/01/2001 |
100,000,000.00 |
EXPORT - IMPORT BANK OF INDIA |
CENTRE ONE; WORLD TRADE CENTRE, CUFFE PARADE, MUMBAI, MAHARASHTRA - 400005, INDIA |
|
|
27 |
90103221 |
01/12/2000 |
30,000,000.00 |
INDIAN BANK |
BHADRA MISSION ROAD, AHMEDABAD, GUJARAT - 380001, INDIA |
|
|
28 |
90103219 |
29/11/2000 |
9,000,000.00 |
CORPORATION BANK |
NVRANGPURA BRANCH, AHMEDABAD, GUJARAT, INDIA |
|
|
29 |
90103209 |
29/09/2000 |
60,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD, AHMEDABAD, GUJARAT -380009, INDIA |
|
|
30 |
90103170 |
18/01/2001 * |
100,000,000.00 |
EXPORT - IMPORT BANK OF INDIA |
CENTRE ONE; WORLD TRADE CENTRE, CUFFE PARADE, MUMBAI, MAHARASHTRA - 400005, INDIA |
|
|
31 |
90103160 |
18/01/2001 * |
450,000,000.00 |
ICICI LIMITED |
ICICI TOWERS, BANDRA KURLA COMPLEX; BANDRA, MUMBAI, MAHARASHTRA - 400051, INDIA |
- |
|
32 |
90103142 |
12/09/2005 * |
780,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT - 380009, INDIA |
- |
|
33 |
90103141 |
12/09/2012 * |
2,100,000,000.00 |
BANK OF BARODA |
CORPORATE FINANCIAL SERVICES BRANCH, 1ST FLOOR, BOB TOWERS, OPP. LAW GARDEN, ELLISBRDIGE, AHMEDABAD, GUJARAT - 380009, INDIA |
B58309642 |
|
34 |
90103099 |
09/11/1995 * |
11,200,000.00 |
BANK OF BARODA |
ASHRAM ROAD BRANCH, AHMEDABAD, GUJARAT - 380009, INDIA |
- |
|
35 |
90314778 |
16/07/1994 * |
80,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD, AHMEDABAD, GUJARAT, INDIA |
- |
|
36 |
90314702 |
13/02/1991 |
25,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD, AHMEDABAD, GUJARAT, INDIA |
- |
|
37 |
90314186 |
06/10/1988 |
3,000,000.00 |
BANK OF BARODA |
ASHRAM ROAD, AHMEDABAD, GUJARAT, INDIA |
- |
|
38 |
90378926 |
16/07/1988 |
3,000,000.00 |
ORISSA STATE FINANCIAL CORPORATION |
OMP SQUARE, CUTTACK, ORISSA, INDIA |
- |
|
39 |
90378866 |
23/04/1991 * |
36,000,000.00 |
UNITED BANK OF INDIA |
CUTTACK, CUTTACK, ORISSA, INDIA |
- |
|
40 |
90313496 |
14/05/1992 * |
200,000.00 |
BANK OF BARODA |
ASHRAM ROAD, AHMEDABAD, GUJARAT, INDIA |
- |
|
41 |
90378785 |
11/02/1985 * |
1,800,000.00 |
INDUSTRIAL PROMOTION AND INVESTMENT CORPORATION OF |
JANPATH, BHUBNESHWAR, ORISSA, INDIA |
- |
FIXED ASSETS:
·
Freehold Land
·
Leasehold Land
·
Building
·
Plant and Machinery
·
Furniture and Fixture
·
Office Equipments
·
Vehicles
·
Live Stock
PRESS RELEASE:
CADILA
PHARMACEUTICALS TO FOCUS ON INTRODUCING AFFORDABLE INNOVATIVE DRUGS
September 25, Samba,
Jammu:
Founded by the doyen of the Indian Pharmaceuticals industry Shri Indravadan A. Modi, Pharma Major Cadila Pharmaceuticals is all set to take a quantum leap by introducing new and innovative drugs in the global market in near future.
Cadila Pharmaceuticals has been research oriented company right from its inception is investing heavily in research activities targeting the key therapeutic areas like Tuberculosis, various types of cancer, novel vaccine adjuvants, Sepsis management and therapeutic vaccine for pancreatic cancer.
The company has one of the best Research and Development (R and D) setups in India, manned by more than three hundred and fifty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering.
Speaking about the company’s vision, philosophy and future plans Dr. Rajiv I Modi, Chairman and Managing Director said, “Cadila Pharmaceuticals will dedicatedly follow philosophy of the Founder Chairman Shri I.A. Modi to offer quality medicines at an affordable price. The company, in recent past has introduced world’s first five-in-one innovative product ‘Polycap’ for Cardiovascular diseases (CVDs) and anti tuberculosis drug ‘Risorine’ with boosted Rifampicin which has better compliance less side effects. Continuing this trend, Cadila Pharmaceuticals will offer many more innovative products in time to come.”
Dr. Modi was interacting with media at Indravadan A. Modi memorial lecture series launch instituted by CSIR-Indian Institute of Integrative Medicine (IIIM) on the eve of 70th Foundation Day of the institute. Dr. Modi presided over this event and delivered presidential remarks.
Cadila Pharmaceuticals is the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed five more INDs from USFDA. Of the five INDs filed, one is for pulmonary tuberculosis; the trial is supported by Department of Biotechnology, Govt. of India. The rest four are for various types of cancers, e.g., Lung Cancer, Prostrate cancer, Bladder Cancer and Melanoma. Thus all the INDs are for providing solutions to major global health care problems. The clinical trials on Prostate cancer, Lung cancer and Bladder cancer are supported by Department of Science and Technology to encourage innovations.
With a view to boost the research activities, the company has also entered in Public-Private partnerships with premier research institutions of the country for developing diagnostic, preventive and curative pharmaceutical and diagnostic products. Innovations that have resulted from such partnerships include ‘Immuvac’ – a unique immuno-modulator that has various applications including reducing duration of therapy for treatment of multi drug resistant tuberculosis and multibacillary leprosy, ‘NEVA’ - a rapid HIV detection kit and more recently Risorine – the world’s first boosted-Rifampicin containing fixed-dose combination for use as an anti-tubercular drug.
Cadila Pharmaceuticals Limited has also entered into strategic alliances to broaden its horizons. CPL Biologicals, a joint venture with Novavax, Inc. USA formed in 2009, will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India. In addition, CPL Biologicals has set up manufacturing facility at Dholka, Ahmedabad in the state of Gujarat, to develop, produce and sell products such as seasonal influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based on Novavax’s virus-like-particle (VLP) vaccine technology. StemCyte India which is into Umbilical Cord Blood Stem Cells Banking is a joint venture of Cadila Pharmaceuticals with StemCyte Inc. USA and Apollo group. Cadila Pharmaceuticals has also entered into a joint venture with Apollo Hospitals Group to manage Apollo Hospital, Ahmedabad.
CADILA
PHARMACEUTICALS SECURES WELLCOME TRUST AWARD
WELLCOME TRUST
SUPPORTS CADILA PHARMACEUTICALS’ PREVENTIVE APPROACH TOWARDS COMBAT CARDIO
VASCULAR DISEASES
Ahmedabad, 29 November, 2010 – Ahmedabad based Pharma major Cadila
Pharmaceuticals Limited has received a prestigious Wellcome Trust Award under
the new R and D for Affordable Healthcare in India initiative to support a
phase III clinical trial of PolycapTM, a combination pill to reduce the risk of
Cardiovascular diseases.
Cardio Vascular Diseases (CVD), predominantly heart disease and stroke, account
for around 30% of all deaths around the world. The PolycapTM offers a primary
prevention strategy to individuals who are at high risk for these illnesses.
PolycapTM comprises three blood pressure reducing agents, including a diuretic
and a beta blocker, together with a cholesterol-lowering
statin. All of the agents have been chosen based on the evidence of their
reducing cardiovascular risk and generic drug status.
The combination pill has already been tested in over 2000 volunteers across 50
centers in India as part of The Indian PolycapTM Study (TIPS) published in the
Lancet in 2009. Results from that phase II trial found that use of the drug
reduces the risk of coronary heart disease by 62% and stroke by 48%.
Speaking of the award, Mr. Indravadan Modi, Chairman of Cadila
Pharmaceuticals said, “We are delighted that our innovative product has gained
recognition by the UK’s leading biomedical foundation, the Wellcome Trust. This
award endorses our efforts in providing research-based revolutionary products
in the cardio care segment.”
The Wellcome Trust award will support the study of at least 5,000 individuals
with no previous history of heart attack or stroke. The placebo-controlled
trial will recruit men over the age of 55 and women over 60 that have been
identified as being at increased risk of CVD through a questionnaire based on
family history and lifestyle factors. The investigators will assess whether
taking PolycapTM for a period of five years can cut the risk of CVD, by
monitoring the incidence of death due to heart attack, non-fatal heart attack,
and non-fatal stroke.
Dr Nick Dunster, Senior Business Analyst at the Wellcome Trust commented:
“Cadila Pharmaceuticals has already reported positive results from previous
clinical trials and we look forward to seeing how PolycapTM performs in this
larger phase III trial. CVD is a global problem, so a drug that can cut the
risk for susceptible individuals has the potential to make a huge impact on
human health the world over, not just in India.”
ABOUTCADILA PHARMACEUTICALS LIMITED.
Cadila Pharmaceuticals Limited is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. It is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art Research and Development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists. The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) cleared by USFDA. The company has manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia. Cadila Pharmaceuticals has recently emerged on the World map with the development of Polycap - a novel and world’s first drug combination for prevention of Cardiovascular Heart Disease.
CPL Biologicals is a newly formed company evolved from a joint venture by Cadila Pharmaceuticals Limited and Novavax, Inc. CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India using technology contributed from Novavax and Cadila Pharmaceuticals. In addition, CPL Biologicals will establish manufacturing facilities in India and develop, produce and sell products such as seasonal influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based on Novavax’s virus-like-particle (VLP) vaccine technology.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other official
proceeding for making any prohibited payments or other improper payments to
government officials for engaging in prohibited transactions or with designated
parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.16 |
|
|
1 |
Rs.97.77 |
|
Euro |
1 |
Rs.82.78 |
INFORMATION DETAILS
|
Information
Gathered by : |
JML |
|
|
|
|
Report Prepared
by : |
VRN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
4 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
YES |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
55 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely
sound financial base with the strongest capability for timely payment of
interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working
capital. No caution needed for credit transaction. It has above average
(strong) capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial &
operational base are regarded healthy. General unfavourable factors will not cause
fatal effect. Satisfactory capability for payment of interest and principal
sums |
Fairly
Large |
|
41-55 |
Ba |
Overall operation is
considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial
difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are
apparent. Repayment of interest and principal sums in default or expected to
be in default upon maturity |
Limited
with full security |
|
<10 |
C |
Absolute credit risk
exists. Caution needed to be exercised |
Credit
not recommended |
|
-- |
NB |
New
Business |
-- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.